

## Special Issue

# Host Immunity and Vaccines for Respiratory Pathogens

### Message from the Guest Editors

We invite researchers to contribute to an upcoming Special Issue of *Vaccines* focusing on “Host Immunity and Vaccines for Respiratory Pathogens”. Respiratory infections, including influenza, RSV, SARS-CoV-2, and emerging pathogens, remain a global health challenge. This Special Issue aims to explore advances in understanding host–pathogen interactions, immune evasion mechanisms, and innovations in vaccine design, evaluation, and deployment. We welcome original research articles, reviews, and clinical studies addressing topics such as the following:

- Innate/adaptive immune responses to respiratory pathogens;
- Novel vaccine platforms (mRNA, viral vectors, etc.) and adjuvants;
- Correlates of protection and vaccine efficacy in diverse populations;
- Mucosal immunity and respiratory tract-targeted strategies;
- Challenges in vaccine equity and pandemic preparedness;
- Real world effectiveness of human vaccines.

We encourage early submissions to ensure timely consideration. Join us in advancing knowledge to combat respiratory pathogens and safeguard global health.

---

### Guest Editors

Dr. Hanqing He

Zhejiang Provincial Center for Disease Control and Prevention,  
Hangzhou, China

Dr. Yuxia Liang

Zhejiang Provincial Center for Disease Control and Prevention,  
Hangzhou, China

---

### Deadline for manuscript submissions

31 January 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/241586](https://mdpi.com/si/241586)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).